Mallinckrodt's expansion and relocation of its pharmaceutical research and development laboratory operations are under way. The 65,000-sq-ft facility, located on Marshall Road in Webster Groves, St. Louis, Mo, is slated for completion in the spring of 2005. The renovation will allow for a significant increase in Mallinckrodt's pharmaceutical research capabilities in St. Louis. It also represents the health care company's commitment to ongoing development of innovative generic drug products for human use.
A large segment of the research scientists currently working at Mallinckrodt's St. Louis production plant will relocate to the new facility upon its completion. Furthermore, the company anticipates adding 20 to 25 researchers over the next year. When up and running, the facility will house about 100 individuals. The existing St. Louis research facilities will be redesigned to meet the expanding needs of the company's chemical business.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs